Anchor Capital Advisors LLC Has $94.99 Million Holdings in McKesson Co. (NYSE:MCK)

Anchor Capital Advisors LLC reduced its position in shares of McKesson Co. (NYSE:MCK - Free Report) by 6.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 205,170 shares of the company's stock after selling 13,775 shares during the period. McKesson comprises about 2.5% of Anchor Capital Advisors LLC's holdings, making the stock its 2nd largest holding. Anchor Capital Advisors LLC owned about 0.15% of McKesson worth $94,989,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of MCK. Addison Advisors LLC lifted its holdings in McKesson by 7.9% during the 4th quarter. Addison Advisors LLC now owns 299 shares of the company's stock worth $138,000 after buying an additional 22 shares in the last quarter. Keystone Financial Services boosted its holdings in McKesson by 2.1% in the fourth quarter. Keystone Financial Services now owns 1,192 shares of the company's stock valued at $552,000 after purchasing an additional 24 shares during the period. Austin Private Wealth LLC grew its stake in McKesson by 2.5% during the 4th quarter. Austin Private Wealth LLC now owns 1,094 shares of the company's stock worth $506,000 after purchasing an additional 27 shares in the last quarter. Quent Capital LLC increased its holdings in McKesson by 2.2% during the 4th quarter. Quent Capital LLC now owns 1,240 shares of the company's stock worth $574,000 after purchasing an additional 27 shares during the period. Finally, Kanawha Capital Management LLC raised its position in McKesson by 4.7% in the 4th quarter. Kanawha Capital Management LLC now owns 607 shares of the company's stock valued at $281,000 after purchasing an additional 27 shares in the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at McKesson

In other McKesson news, EVP Leann B. Smith sold 186 shares of McKesson stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the sale, the executive vice president now owns 1,511 shares of the company's stock, valued at approximately $749,456. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Brian S. Tyler sold 3,473 shares of the company's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the transaction, the chief executive officer now directly owns 43,445 shares of the company's stock, valued at approximately $22,789,074.75. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Leann B. Smith sold 186 shares of the firm's stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total transaction of $92,256.00. Following the completion of the sale, the executive vice president now owns 1,511 shares of the company's stock, valued at approximately $749,456. The disclosure for this sale can be found here. Company insiders own 0.21% of the company's stock.

McKesson Price Performance

Shares of NYSE:MCK traded down $7.21 on Monday, reaching $536.09. The company's stock had a trading volume of 1,034,521 shares, compared to its average volume of 692,065. McKesson Co. has a 52-week low of $352.34 and a 52-week high of $544.81. The stock has a market capitalization of $70.45 billion, a P/E ratio of 24.29, a PEG ratio of 1.44 and a beta of 0.45. The stock's 50-day moving average is $528.65 and its two-hundred day moving average is $490.49.

McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $7.74 EPS for the quarter, beating the consensus estimate of $7.05 by $0.69. McKesson had a negative return on equity of 262.63% and a net margin of 0.99%. The firm had revenue of $80.90 billion during the quarter, compared to the consensus estimate of $77.93 billion. During the same period in the prior year, the business earned $6.90 EPS. The firm's revenue was up 14.8% compared to the same quarter last year. Equities analysts forecast that McKesson Co. will post 27.59 earnings per share for the current fiscal year.

McKesson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, July 1st. Stockholders of record on Monday, June 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 0.46%. The ex-dividend date is Friday, May 31st. McKesson's payout ratio is 11.24%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. StockNews.com upgraded shares of McKesson from a "buy" rating to a "strong-buy" rating in a research note on Thursday. SVB Leerink began coverage on McKesson in a report on Monday, February 26th. They issued an "outperform" rating and a $600.00 target price on the stock. Barclays initiated coverage on McKesson in a report on Wednesday, January 3rd. They set an "overweight" rating and a $537.00 price target for the company. Morgan Stanley increased their price objective on McKesson from $522.00 to $548.00 and gave the company an "overweight" rating in a report on Monday, April 15th. Finally, UBS Group boosted their target price on McKesson from $575.00 to $620.00 and gave the stock a "buy" rating in a research note on Wednesday, March 6th. Two investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $533.50.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.